Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

• Published in: Cancers 2021-04, Vol.13 (8), p.1845
• Main Authors: Prat, Mélissa, Salon, Marie, Allain, Thibault, Dubreuil, Olivier, Noël, Grégory, Preisser, Laurence, Jean, Bérangère, Cassard, Lydie, Lemée, Fanny, Tabah-Fish, Isabelle, Pipy, Bernard, Jeannin, Pascale, Prost, Jean-François, Barret, Jean-Marc, Coste, Agnès
• Format: Article
• Language: English
• Subjects: Adaptive immunity; Antibodies; Antibody-dependent cell-mediated cytotoxicity; Antitumor agents; Biopsy; Cancer; Cancer therapies; CD4 antigen; CD8 antigen; Cell activation; Chemokines; Colorectal cancer; Cytokines; Cytotoxicity; Effector cells; Growth factors; Gynecology; Immune checkpoint; Immunoglobulins; Immunomodulation; Inflammation; Life Sciences; Lymphocytes; Lymphocytes T; Macrophages; Microenvironments; Monoclonal antibodies; Opsonization; Ovarian cancer; Patients; Pembrolizumab; Phagocytosis; Phenotypes; Tumor cells; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13081845

AMHRII, the anti-Müllerian hormone receptor, is selectively expressed in normal sexual organs but is also re-expressed in gynecologic cancers. Hence, we developed murlentamab, a humanized glyco-engineered anti-AMHRII monoclonal antibody currently in clinical trial. Low-fucosylated antibodies are known to increase the antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) potency of effector cells, but some preliminary results suggest a more global murlentamab-dependent activation of the immune system. In this context, we demonstrate here that the murlentamab opsonization of AMHRII-expressing ovarian tumor cells, in the presence of unstimulated- or tumor-associated macrophage (TAM)-like macrophages, significantly promotes macrophage-mediated ADCC and shifts the whole microenvironment towards a pro-inflammatory and anti-tumoral status, thus triggering anti-tumor activity. We also report that murlentamab orients both unstimulated- and TAM-like macrophages to an M1-like phenotype characterized by a strong expression of co-stimulation markers, pro-inflammatory cytokines and chemokines, favoring T cell recruitment and activation. Moreover, we show that murlentamab treatment shifts CD4 Th1/Th2 balance towards a Th1 response and activates CD8 T cells. Altogether, these results suggest that murlentamab, through naïve macrophage orientation and TAM reprogrammation, stimulates the anti-tumor adaptive immune response. Those mechanisms might contribute to the sustained clinical benefit observed in advanced cancer patients treated with murlentamab. Finally, the enhanced murlentamab activity in combination with pembrolizumab opens new therapeutic perspectives.